Will Berinert's US OK for self-administration put Shire's Firazyr on the run?
This article was originally published in Scrip
Executive Summary
With the US FDA granting CSL Behring permission to market its hereditary angioedema (HAE) drug Berinert, a plasma-derived C1 inhibitor replacement product, as a self-administered medicine for acute abdominal, facial or laryngeal swelling attacks, the company may have Shire's Firazyr (icatibant) on the run, although as a subcutaneously administered treatment, the latter may still win out.